Sort   by:  
 Page size 
TranscriptomicsEGI-1 cell line treated with Saracatinib vs EGI-1 cell line untreated; EGI-1 xenograft treated with Saracatinib vs EGI-1 untreated
Biliary tract carcinoma (BTC) has a poor prognosis due to limited treatment options. There is therefore urgent need to identify new targets and to design innovative therapeutic approaches. Among potential candidate molecules, we evaluated the non-receptor tyrosine kinase Src, observing promising ant...
ORGANISM(S): Homo sapiens 
2012-08-02 | E-GEOD-36622 | biostudies-arrayexpress
TranscriptomicsHER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
HER2 targeting with trastuzumab has changed the prognosis of breast cancer patients carrying amplification and/or overexpression of this oncogene. Despite this progress, however, resistance to trastuzumab occurs in the vast majority of patients. Newer anti-HER2 therapies, like the dual tyrosine-kina...
ORGANISM(S): Homo sapiens 
2010-12-15 | E-GEOD-17630 | biostudies-arrayexpress
TranscriptomicsGene profiling, mutations and expression of epidermal growth factor receptor in androgen-dependent prostate cancer
We analyzed mutations in Epidermal Growth Factor Receptor (EGFR) Tyrosine kinase (TK) domain, EGFR expression and gene profiling in prostate carcinoma (PC) in order to find out molecular prognostic markers and supply a proof for EGFR targeted therapies. 100 glyofixx-fixed, paraffin-embedded PC spec...
ORGANISM(S): Homo sapiens 
2011-06-30 | E-GEOD-16120 | biostudies-arrayexpress
Sort   by:  
 Page size